EXEL - Exelixis starts phase 3 trial of zanzalintinib/Opdivo combo for kidney cancer

• Exelixis ( NASDAQ: EXEL ) said it started a phase 3 trial of zanzalintinib to treat a type of kidney cancer.
• The study, dubbed STELLAR-304, is evaluating zanzalintinib (XL092) in combination with Bristol-Myers Squibb's Opdivo (nivolumab), versus Pfizer's Sutent (sunitinib) to treat patients with advanced non-clear cell renal cell carcinoma (nccRCC).
• The company added that STELLAR-304, which will enroll ~291 patients, is the second phase 3 trial evaluating zanzalintinib — a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced tumor types.
• "In September at ESMO 2022, we presented zanzalintinib phase 1 data which demonstrated promising clinical activity across a range of tumors with a manageable safety profile. We were particularly encouraged by the activity of zanzalintinib in advanced kidney cancer patients, including patients with non-clear cell subtypes," said Vicki Goodman, executive vice president, Product Development & Medical Affairs, and chief medical officer, Exelixis.

For further details see: